Challenges in COVID-19 vaccination

Vaccinations are considered a promising way out of the COVID-19 pandemic. Although several vaccines are already in use, there are still enormous challenges ahead. For example, because vaccines are not immediately available on a large scale, equitable international allocation must be clarified. Lack of public trust in vaccines is also a problem that needs to be addressed. International experts will discuss these issues, as well as the characteristics of the different types of vaccines, on the occasion of an English-language virtual panel discussion on Wednesday, February 3.


Leopoldina International Virtual Panel Discussion

“Challenges in COVID-19 Vaccination”

Wednesday, 3 February 2021

10:00 a.m.-11:15 a.m. GMT (London)

11:00 a.m.-12:15 p.m. (Berlin, Oslo)

3:30 p.m.-4:45 p.m. (New Delhi)

The event is jointly organized by the German National Academy of Sciences Leopoldina and the Indian National Science Academy (INSA).

Debating at the podium:

  • Richard Hatchett, MD

    Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations, Oslo, Norway
  • Ingmar Hoerr, PhD

    mRNA technology pioneer and Co-Founder of CureVac, Tübingen, Germany
  • Professor Gagangdeep Kang, PhD, member of the INSA

    Chair of the Immunization Technical Advisory Group for the WHO South East Asian Region, New Delhi, India
  • Professor Heidi Larson, PhD

    Director of The Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, United Kingdom

The virtual live event will be moderated by Professor Regina T. Riphahn, PhD, Vice President German National Academy of Sciences Leopoldina, and Professor of Statistics and Empirical Economics, University of Erlangen-Nuremberg, Germany.

With this discussion, the Leopoldina continues its series Leopoldina International. The objective of the virtual podium discussions, organized in cooperation with the Leopoldina’s global partners, is to promote scientific dialogue among the international scientific community and with the public. Previous topics have been “COVID-19 and Multimorbidity: How to Deal with Multiple Infectious Diseases in Parallel?”, “The Hidden Crisis: Mental Health in Times of COVID-19” and “Contact Tracing Apps: Promising Tool in the Fight Against COVID-19?”.

###

Further information can be found at:

http://www.

leopoldina.

org/

livp

.

Follow the Leopoldina on Twitter:

http://www.

twitter.

com/

leopoldina

The event is open to all interested parties. Participation is free of charge. Prior registration is required via the following link:

https:/

/

zoom.

us/

webinar/

register/

WN_TLoDwCq8Tf2c0QBDNyXpYg

After successful registration, you will receive a confirmation e-mail with a dial-in link for the webinar and a password. You will also receive information on how to dial into the event by phone. When using the Zoom video conferencing system, the privacy policy of the provider applies:

https:/

/

zoom.

us/

privacy


About the German National Academy of Sciences Leopoldina

As the German National Academy of Sciences, the Leopoldina provides independent science-based policy advice on matters relevant to society. To this end, the Academy develops interdisciplinary statements based on scientific findings. In these publications, options for action are outlined; making decisions, however, is the responsibility of democratically legitimized politicians. The experts who prepare the statements work in a voluntary and unbiased manner. The Leopoldina represents the German scientific community in the international academy dialogue. This includes advising the annual summits of Heads of State and Government of the G7 and G20 countries. With 1,600 members from more than 30 countries, the Leopoldina combines expertise from almost all research areas. Founded in 1652, it was appointed the National Academy of Sciences of Germany in 2008. The Leopoldina is committed to the common good.

This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-01/l-cic012721.php

withyou android app